Currently, the expression of PD-L1 in tumor cells is the biomarker used clinically to select the treatment for NSCLC patients without driver mutations, and it correlates with better response rates, particularly when it is higher than 50% [15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.